Signaling by ERBB4 (Homo sapiens)

From WikiPathways

Jump to: navigation, search
11, 13, 14, 17, 19...3819, 538, 27, 8536, 46654519, 53, 705538452, 13, 3636, 40, 836514, 17, 22, 29, 42...818138381745818123, 6981268127, 8527, 8517, 5327, 85668126386513, 40, 83236538458138816936, 4619, 53, 6581mitochondrial matrixcytosolnucleoplasmUBC(305-380) ESR1 GABRA1 ERBB4jmAcyt1s80 ERBB4jmAcyt2s80 p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform ERBB4jmAcyt1s80 UBC(77-152) ERBB4jmAcyt2s80 APOE gene UBC(305-380) MyrG-p-Y419-SRC p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform GABRQ ERBB4 ADAM17 gamma-secretasecomplexERBB4 JM-A CYT-2 isoform PI(3,4,5)P3EGF-like ligands ERBB4 JM-A CYT-2 isoform EGF-like ligands ERBB4s80:p-Y694-STAT5A:CSN2 geneUBC(609-684) GABRB1 EGFR WWP1 ERBB4jmAcyt1s80 Activation of NMDAreceptors andpostsynaptic eventsGABRB3 CXCL12(22-93)ATPGABRG2 RPS27A(1-76) ERBB4jmAcyt1s80 GTPAPH1A UBC(457-532) MXD4 gene ERBB4s80 UBC(305-380) NRG2 YAP1 p21 RAS:GDPp-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform ERBB4 JM-A CYT-1 isoform ESR1 ESR1 ERBB4jmAcyt1s80 CSN2 geneWWP1/ITCHNeuregulins ERBB4jmAcyt2s80 CSN2 gene TAB2 S-Farn-Me-PalmS KRAS4A PGR geneERBB4jmAcyt1s80 EGF-like ligands ESTG ERBB4jmAcyt1s80 ERBB4jmAcyt1s80 ERBB4jmAcyt1s80 ERBB4jmAcyt1s80:MXD4geneAPOE geneERBB4s80:ESR1:estrogen:CXCL12 geneESR1 ADAP1 gene CXCL12 gene APOEUBA52(1-76) PGRGRB2:SOS1:p-Y349,350-SHC1:p-ERBB4SHC1Neuregulins ERBB4NEDD4PSEN1(1-298) GABRB1 UBC(229-304) GABA ERBB4s80:ADAP1 geneERBB4s80:TAB2:NCOR1:S100B genep-ERBB4cyt1 homodimers TAB2 UBC(609-684) GABRG3 ERBB4s80:ESR1:estrogen:ERBB4 geneEGF-like ligands UBC(229-304) EGF-like ligands NRGs/EGF-likeligandsATPUb-ERBB4:WWP1/ITCHUBB(153-228) Neuregulins UBA52(1-76) UBB(153-228) STMN1 geneERBB4s80:YAP1UBB(1-76) GABRB2 p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform NRG1 ERBB4jmAcyt1ECD ERBB4cyt1 homodimers ERBB4jmAcyt2m80 ADPp-ERBB4cyt1 homodimers Neuregulins UBC(77-152) GRB2-1 ERBB4jmAcyt1s80 ATPNeuregulins ERBB4 gene ERBB4jmAcyt1s80 ERBB4jmAcyt2s80 p-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform PGR gene MXD4ERBB4s80:WWOXERBB4/m80/s80:WWP1/ITCHNRGs/EGF-likeligands:ERBB4ADAP1ERBB4jmAcyt1s80dimerSPARCp-ERBB4cyt1 homodimers NCSTN ERBB3-1 ERBB4jmAcyt1s80:NEDD4EGF-like ligands ERBB4jmAcyt1s80 ERBB4s80:TAB2:NCOR1SHC1 ITCH GRB2-1 ERBB4jmAcyt2s80 ERBB4m80 ERBB4 JM-A CYT-1 isoform S100BDLG4WWP1 ERBB4jmAcyt1s80 p-Y349,Y350-SHC1 GABRA1 Neuregulins GABRB2 EGF-like ligands ERBB4jmAcyt2s80 MXD4 geneEGF-like ligands ERBB4jmAcyt2s80 ERBB4 JM-A CYT-1 isoform ERBB4jmAcyt1s80 ERBB3-1 ERBB4 ERBB4 homodimersERBB4s80:MyrG-p-Y419-SRCS-Farn-Me PalmS NRAS S-Farn-Me-2xPalmS HRAS ERBB4 JM-B CYT-1 isoform S-Farn-Me-2xPalmS HRAS UBC(381-456) p-Y694-STAT5A PIK3CA:PIK3R1UbRPS27A(1-76) NRG1 p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform UBC(229-304) NRG2 ERBB4 JM-A CYT-2 isoform Neuregulins UBC(533-608) ERBB4s80 SPARC geneTAB2:NCOR1ERBB4s80GDPUBA52(1-76) PIK3R1 NCOR1 ADPERBB4jmAcyt2s80 ESR1 NEDD4 p-Y694-STAT5A NRG2:p-ERBB4homodimers:GABRA1heteropentamers:GABASOS1 Neuregulins ERBB4s80:TAB2:NCOR1GDP GABRG2 UBC(533-608) ERBB4jmAcyt1s80 ERBB4jmAcyt1s80 ESR1:ESTGS-Farn-Me PalmS NRAS EGF-like ligands UBB(77-152) Neuregulins UBC(153-228) GFAP geneERBB4m80 ERBB4s80:p-Y694-STAT5AUBC(77-152) p-ERBB4cyt1homodimersp-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform NRG2:p-ERBB4cyt1 homodimers S100B gene PSENEN ERBB4 JM-B CYT-1 isoform ERBB4jmAcyt2ECD RPS27A(1-76) ERBB4jmAcyt2s80 YAP1- and WWTR1(TAZ)-stimulatedgene expressionp-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform EGF-like ligands p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform ERBB4s80:STMN1 geneNRG2:p-ERBB4cyt1 homodimers SHC1:p-ERBB4MyrG-p-Y419-SRCp-Y349,Y350-SHC1 ERBB4jmAcyt1m80 UBC(1-76) ERBB4s80:p-Y694-STAT5AGABRA1heteropentamers:GABAp-Y694-STAT5A UBB(153-228) NRG1/2:ERBB3p-Y694-STAT5AhomodimerEGF-like ligands NRG2 YAP1ERBB4:EGFRheterodimerERBB4jmAcyt1s80 UBC(153-228) NCOR1 Prolactin receptorsignalingEGF-like ligands ERBB4jmAcyt1s80 NEDD4 DLG4 GABRQ GABRG3 ESTG ERBB4s80:YAP1ERBB4jmAcyt2s80 ERBB4jmAcyt2s80 ERBB4jmAcyt1s80 GRB2-1:SOS1ERBB4 CYT-1 isoforms ERBB4jmAcyt2s80 S-Farn-Me KRAS4B WWP1 S-Farn-Me KRAS4B UBC(153-228) p-Y1046,Y1178,Y1232-ERBB4 JM-B CYT-1 isoform EGF-like ligands ADAP1 geneADPUBC(1-76) ERBB4jmAcyt2s80 PIK3CA Signaling by HippoUBC(457-532) ERBB4_ECDERBB4jmAcyt2s80 p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform ESTG ERBB4jmAcyt1s80 ERBB4jmAcyt1s80 NCOR1 GFAPERBB4jmAcyt1s80 ERBB4jmAcyt2s80 PIK3CA ERBB4s80TAB2 p-ERBB4 homodimersERBB4jmAcyt1s80 EGF Neuregulins TAB2 WWOXITCH ERBB4m80APH1B ERBB4jmAcyt2s80 ERBB4m80 UBC(381-456) NRG2 GFAP gene PSEN2(1-297) EGF ERBB4s80:TAB2:NCOR1:GFAP geneNCOR1 ERBB4:ERBB3heterodimerS100B genePIK3R1 ITCH Neuregulins WWOX ERBB4s80:ESR1:estrogenNRG2:p-ERBB4homodimersERBB4jmAcyt1s80dimerCXCL12 geneERBB4s80:SPARC geneNeuregulins CSN2STMN1 gene TAB2 ADAM17Zn2+ S-Farn-Me-PalmS KRAS4A ERBB4jmAcyt2s80 YAP1 ERBB4jmAcyt2s80 PI(4,5)P2UBB(77-152) UBC(609-684) GTP ERBB4jmAcyt1s80 ERBB4 RAF/MAP kinasecascadeERBB4s80 UBB(1-76) EGF:EGFRp-Y694-STAT5A ERBB4jmAcyt1s80 p-Y349,350-SHC1:p-ERBB4ERBB4 JM-A CYT-2 isoform ERBB4 JM-A CYT-2 isoform NCOR1 ERBB4:DLG4SPARC gene UBB(1-76) ERBB4 CYT-1 isoforms UBC(381-456) ERBB4/ERBB4m80/ERBB4s80ERBB4jmAcyt2s80 ERBB4s80EGFR PI3K:p-ERBB4cyt1ERBB4jmAcyt2s80 ESTG ERBB4s80:ESR1:estrogen:PGR geneSTMN1UBC(457-532) SOS1 ERBB4jmAcyt1s80 UBB(77-152) GABA ERBB4 JM-B CYT-1 isoform p21 RAS:GTPERBB4jmAcyt1s80 UBC(1-76) ERBB4jmAcyt2s80 ERBB4 geneUb-ERBB4jmAcyt1s80:NEDD4p-ERBB4 JM-Ahomodimersp-Y1056,Y1188,Y1242-ERBB4 JM-A CYT-1 isoform p-ERBB4cyt1 homodimers ERBB4 JM-A CYT-2 isoform PIP3 activates AKTsignalingGABRB3 ERBB4s80:APOE genePSEN1(299-467) ERBB4jmAcyt2s80 PSEN2(298-448) Neuregulins ESTG UBC(533-608) 541, 34, 634516, 594-7, 9, 15...3, 12, 24, 28, 49...10, 25, 33, 753849, 744569


Description

ERBB4, also known as HER4, belongs to the ERBB family of receptors, which also includes ERBB1 (EGFR/HER1), ERBB2 (HER2/NEU) and ERBB3 (HER3). Similar to EGFR, ERBB4 has an extracellular ligand binding domain, a single transmembrane domain and a cytoplasmic domain which contains an active tyrosine kinase and a C-tail with multiple phosphorylation sites. At least three and possibly four splicing isoforms of ERBB4 exist that differ in their C-tail and/or the extracellular juxtamembrane regions: ERBB4 JM-A CYT1, ERBB4 JM-A CYT2 and ERBB4 JM-B CYT1 (the existence of ERBB4 JM-B CYT2 has not been confirmed).

ERBB4 becomes activated by binding one of its seven ligands, three of which, HB-EGF, epiregulin EPR and betacellulin BTC, are EGF-like (Elenius et al. 1997, Riese et al. 1998), while four, NRG1, NRG2, NRG3 and NRG4, belong to the related neuregulin family (Tzahar et al. 1994, Carraway et al. 1997, Zhang et al. 1997, Hayes et al. 2007). Upon ligand binding, ERBB4 forms homodimers (Sweeney et al. 2000) or it heterodimerizes with ERBB2 (Li et al. 2007). Dimers of ERBB4 undergo trans-autophosphorylation on tyrosine residues in the C-tail (Cohen et al. 1996, Kaushansky et al. 2008, Hazan et al. 1990, Li et al. 2007), triggering downstream signaling cascades. The pathway Signaling by ERBB4 only shows signaling by ERBB4 homodimers. Signaling by heterodimers of ERBB4 and ERBB2 is shown in the pathway Signaling by ERBB2. Ligand-stimulated ERBB4 is also able to form heterodimers with ligand-stimulated EGFR (Cohen et al. 1996) and ligand-stimulated ERBB3 (Riese et al. 1995). Dimers of ERBB4 with EGFR and dimers of ERBB4 with ERBB3 were demonstrated in mouse cell lines in which human ERBB4 and EGFR or ERBB3 were exogenously expressed. These heterodimers undergo trans-autophosphorylation. The promiscuous heteromerization of ERBBs adds combinatorial diversity to ERBB signaling processes. As ERBB4 binds more ligands than other ERBBs, but has restricted expression, ERBB4 expression channels responses to ERBB ligands. The signaling capabilities of the four receptors have been compared (Schulze et al. 2005).

As for other receptor tyrosine kinases, ERBB4 signaling effectors are largely dictated through binding of effector proteins to ERBB4 peptides that are phosphorylated upon ligand binding. All splicing isoforms of ERBB4 possess two tyrosine residues in the C-tail that serve as docking sites for SHC1 (Kaushansky et al. 2008, Pinkas-Kramarski et al. 1996, Cohen et al. 1996). Once bound to ERBB4, SHC1 becomes phosphorylated on tyrosine residues by the tyrosine kinase activity of ERBB4, which enables it to recruit the complex of GRB2 and SOS1, resulting in the guanyl-nucleotide exchange on RAS and activation of RAF and MAP kinase cascade (Kainulainen et al. 2000).

The CYT1 isoforms of ERBB4 also possess a C-tail tyrosine residue that, upon trans-autophosphorylation, serves as a docking site for the p85 alpha subunit of PI3K (Kaushansky et al. 2008, Cohen et al. 1996), leading to assembly of an active PI3K complex that converts PIP2 to PIP3 and activates AKT signaling (Kainulainen et al. 2000).

Besides signaling as a conventional transmembrane receptor kinase, ERBB4 differs from other ERBBs in that JM-A isoforms signal through efficient release of a soluble intracellular domain. Ligand activated homodimers of ERBB4 JM-A isoforms (ERBB4 JM-A CYT1 and ERBB4 JM-A CYT2) undergo proteolytic cleavage by ADAM17 (TACE) in the juxtamembrane region, resulting in shedding of the extracellular domain and formation of an 80 kDa membrane bound ERBB4 fragment known as ERBB4 m80 (Rio et al. 2000, Cheng et al. 2003). ERBB4 m80 undergoes further proteolytic cleavage, mediated by the gamma-secretase complex, which releases the soluble 80 kDa ERBB4 intracellular domain, known as ERBB4 s80 or E4ICD, into the cytosol (Ni et al. 2001). ERBB4 s80 is able to translocate to the nucleus, promote nuclear translocation of various transcription factors, and act as a transcription co-factor. For example, in mammary cells, ERBB4 binds SH2 transcription factor STAT5A. ERBB4 s80 shuttles STAT5A to the nucleus, and actsa as a STAT5A co-factor in binding to and promoting transcription from the beta-casein (CSN2) promoter, and may be involved in the regulation of other lactation-related genes (Jones et al. 1999, Williams et al. 2004, Muraoka-Cook et al. 2008). ERBB4 s80 binds activated estrogen receptor in the nucleus and acts as a transcriptional co-factor in promoting transcription of some estrogen-regulated genes, including progesterone receptor gene NR3C3 and CXCL12 (SDF1) (Zhu et al. 2006). In neuronal precursors, ERBB4 s80 binds the complex of TAB and NCOR1, helps to move the complex into the nucleus, and is a co-factor of TAB:NCOR1-mediated inhibition of expression of astrocyte differentiation genes GFAP and S100B (Sardi et al. 2006).

The C-tail of ERBB4 possesses several WW-domain binding motifs (three in CYT1 isoform and two in CYT2 isoform), which enable interaction of ERBB4 with WW-domain containing proteins. ERBB4 s80, through WW-domain binding motifs, interacts with YAP1 transcription factor, a known proto-oncogene, and is a co-regulator of YAP1-mediated transcription in association with TEAD transcription factors (Komuro et al. 2003, Omerovic et al. 2004). Hence, the WW binding motif couples ERBB4 to the major effector arm of the HIPPO signaling pathway. The tumor suppressor WWOX, another WW-domain containing protein, competes with YAP1 in binding to ERBB4 s80 and prevents translocation of ERBB4 s80 to the nucleus (Aqeilan et al. 2005).

WW-domain binding motifs in the C-tail of ERBB4 play an important role in the downregulation of ERBB4 receptor signaling, enabling the interaction of intact ERBB4, ERBB4 m80 and ERBB4 s80 with NEDD4 family of E3 ubiquitin ligases WWP1 and ITCH. The interaction of WWP1 and ITCH with intact ERBB4 is independent of receptor activation and autophosphorylation. Binding of WWP1 and ITCH ubiquitin ligases leads to ubiquitination of ERBB4 and its cleavage products, and subsequent degradation through both proteasomal and lysosomal routes (Omerovic et al. 2007, Feng et al. 2009). In addition, the s80 cleavage product of ERBB4 JM-A CYT-1 isoform is the target of NEDD4 ubiquitin ligase. NEDD4 binds ERBB4 JM-A CYT-1 s80 (ERBB4jmAcyt1s80) through its PIK3R1 interaction site and mediates ERBB4jmAcyt1s80 ubiquitination, thereby decreasing the amount of ERBB4jmAcyt1s80 that reaches the nucleus (Zeng et al. 2009).

ERBB4 also binds the E3 ubiquitin ligase MDM2, and inhibitor of p53 (Arasada et al. 2005). Other proteins that bind to ERBB4 intracellular domain have been identified by co-immunoprecipitation and mass spectrometry (Gilmore-Hebert et al., 2010), and include transcriptional co-repressor TRIM28/KAP1, which promotes chromatin compaction. DNA damage signaling through ATM releases TRIM28-associated heterochromatinization. Interactions of ERBB4 with TRIM28 and MDM2 may be important for integration of growth factor responses and DNA damage responses.

In human breast cancer cell lines, ERBB4 activation enhances anchorage-independent colony formation in soft agar but inhibits cell growth in a monolayer culture. Different ERBB4 ligands induce different gene expression changes in breast cancer cell lines. Some of the genes induced in response to ERBB4 signaling in breast cancer cell lines are RAB2, EPS15R and GATA4. It is not known if these gene are direct transcriptional targets of ERBB4 (Amin et al. 2004).

Transcriptome and ChIP-seq comparisons of full-length and intracellular domain isoforms in isogenic MCF10A mammary cell background have revealed the diversification of ERBB4 signaling engendered by alternative splicing and cleavage (Wali et al., 2014). ERBB4 broadly affected protease expression, cholesterol biosynthesis, HIF1-alpha signaling, and HIPPO signaling pathways, and other pathways were differentially activated by CYT1 and CYT2 isoforms. For example, CYT1 promoted expression of transcription factors TWIST1 and SNAIL1 that promote epithelial-mesenchymal transition. HIF1-alpha and HIPPO signaling are mediated, respectively, by binding of ERBB4 to HIF1-alpha and to YAP (Paatero et al., 2012, Komuro et al., 2003). ERBB4 increases activity of the transcription factor SREBF2, resulting in increased expression of SREBF2-target genes involved in cholesterol biosynthesis. The mechanism is not known and may involve facilitation of SREBF2 cleavage through ERBB4-mediated PI3K signaling (Haskins et al. 2016).

In some contexts, ERBB4 promotes growth suppression or apoptosis (Penington et al., 2002). Activation of ERBB4 in breast cancer cell lines leads to JNK dependent increase in BRCA1 mRNA level and mitotic cell cycle delay, but the exact mechanism has not been elucidated (Muraoka Cook et al. 2006). The nature of growth responses may be connected with the spliced isoforms expressed. In comparisons of CYT1 vs CYT2 (full-length and ICD) expression in mammary cells, CYT1 was a weaker growth inducer, associated with attenuated MAPK signaling relative to CYT2 (Wali et al., 2014). ERBB4 s80 is also able to translocate to the mitochondrial matrix, presumably when its nuclear translocation is inhibited. Once in the mitochondrion, the BH3 domain of ERBB4, characteristic of BCL2 family members, may enable it to act as a pro apoptotic factor (Naresh et al. 2006).

ERBB4 plays important roles in the developing and adult nervous system. Erbb4 deficiency in somatostatin-expressing neurons of the thalamic reticular nucleus alters behaviors dependent on sensory selection (Ahrens et al. 2015). NRG1-activated ERBB4 signaling enhances AMPA receptor responses through PKC-dependent AMPA receptor exocytosis. This results in an increased excitatory input to parvalbumin-expressing inhibitory neurons in the visual cortex and regulates visual cortical plasticity (Sun et al. 2016). NRG1-activated ERBB4 signaling is involved in GABAergic activity in amygdala which mediates fear conditioning (fear memory) (Lu et al. 2014). Conditional Erbb4 deletion from fast-spiking interneurons, chandelier and basket cells of the cerebral cortex leads to synaptic defects associated with increased locomotor activity and abnormal emotional, social and cognitive function that can be linked to some of the schizophrenia features. The level of GAD1 (GAD67) protein is reduced in the cortex of conditional Erbb4 mutants. GAD1 is a GABA synthesizing enzyme. Cortical mRNA levels of GAD67 are consistently decreased in schizophrenia (Del Pino et al. 2014). Erbb4 is expressed in the GABAergic neurons of the bed nucleus stria terminalis, a part of the extended amygdala. Inhibition of NRG1-triggered ERBB4 signaling induces anxiety-like behavior, which depends on GABAergic neurotransmission. NRG1-ERBB4 signaling stimulates presynaptic GABA release, but the exact mechanism is not known (Geng et al. 2016). NRG1 protects cortical interneurons against ischemic brain injury through ERBB4-mediated increase in GABAergic transmission (Guan et al. 2015). NRG2-activated ERBB4 can reduce the duration of GABAergic transmission by binding to GABA receptors at the postsynaptic membrane via their GABRA1 subunit and promoting endocytosis of GABA receptors (Mitchell et al. 2013). NRG1 promotes synchronization of prefrontal cortex interneurons in an ERBB4 dependent manner (Hou et al. 2014). NRG1-ERBB4 signaling protects neurons from the cell death induced by a mutant form of the amyloid precursor protein (APP) (Woo et al. 2012).

Clinical relevance of ERBB4 has been identified in several contexts. In cancer, putative and validated gain-of-function mutations or gene amplification that may be drivers have been identified at modest frequencies, and may also contribute to resistance to EGFR and ERBB2-targeted therapies. This is noteworthy as ERBB4 kinase activity is inhibited by pan-ERBB tyrosine kinase inhibitors, including lapatinib, which is approved by the US FDA. The reduced prevalence relative to EGFR and ERBB2 in cancer may reflect more restricted expression of ERBB4, or differential signaling, as specific ERBB4 isoforms have been linked to growth inhibition or apoptosis in experimental systems. ERBB2/ERBB4 heterodimers protect cardiomyocytes, so reduced activity of ERBB4 in patients treated with the ERBB2-targeted therapeutic antibody trastuzumab may contribute to the cardiotoxicity of this agent when used in combination with (cardiotoxic) anthracyclines.

With the importance of ERBB4 in developing and adult nervous system, NRG1 and/or ERBB4 polymorphisms, splicing aberrations and mutations have been linked to nervous system disorders including schizophrenia and amyotrophic lateral sclerosis, although these findings are not yet definitive. View original pathway at Reactome.

Comments

Reactome-Converter 
Pathway is converted from Reactome ID: 1236394
Reactome-version 
Reactome version: 75
Reactome Author 
Reactome Author: Orlic-Milacic, Marija

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Goffin V, Binart N, Touraine P, Kelly PA.; ''Prolactin: the new biology of an old hormone.''; PubMed Europe PMC Scholia
  2. Schuchardt BJ, Bhat V, Mikles DC, McDonald CB, Sudol M, Farooq A.; ''Molecular origin of the binding of WWOX tumor suppressor to ErbB4 receptor tyrosine kinase.''; PubMed Europe PMC Scholia
  3. Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D, Bader GD, Sidhu SS, Vandekerckhove J, Gettemans J, Sudol M.; ''Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling.''; PubMed Europe PMC Scholia
  4. Roskoski R.; ''RAF protein-serine/threonine kinases: structure and regulation.''; PubMed Europe PMC Scholia
  5. McKay MM, Morrison DK.; ''Integrating signals from RTKs to ERK/MAPK.''; PubMed Europe PMC Scholia
  6. Plotnikov A, Zehorai E, Procaccia S, Seger R.; ''The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation.''; PubMed Europe PMC Scholia
  7. Wellbrock C, Karasarides M, Marais R.; ''The RAF proteins take centre stage.''; PubMed Europe PMC Scholia
  8. Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS.; ''ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.''; PubMed Europe PMC Scholia
  9. Roberts PJ, Der CJ.; ''Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.''; PubMed Europe PMC Scholia
  10. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R.; ''Glutamate receptor ion channels: structure, regulation, and function.''; PubMed Europe PMC Scholia
  11. Rio C, Buxbaum JD, Peschon JJ, Corfas G.; ''Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.''; PubMed Europe PMC Scholia
  12. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L.; ''The Hippo pathway regulates Wnt/beta-catenin signaling.''; PubMed Europe PMC Scholia
  13. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M, Croce CM.; ''WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function.''; PubMed Europe PMC Scholia
  14. Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C.; ''Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.''; PubMed Europe PMC Scholia
  15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.; ''Mutations of the BRAF gene in human cancer.''; PubMed Europe PMC Scholia
  16. Chardin P, Camonis JH, Gale NW, van Aelst L, Schlessinger J, Wigler MH, Bar-Sagi D.; ''Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.''; PubMed Europe PMC Scholia
  17. Riese DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF.; ''The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.''; PubMed Europe PMC Scholia
  18. Roskoski R.; ''ERK1/2 MAP kinases: structure, function, and regulation.''; PubMed Europe PMC Scholia
  19. Kaushansky A, Gordus A, Budnik BA, Lane WS, Rush J, MacBeath G.; ''System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.''; PubMed Europe PMC Scholia
  20. Turjanski AG, Vaqué JP, Gutkind JS.; ''MAP kinases and the control of nuclear events.''; PubMed Europe PMC Scholia
  21. Brown MD, Sacks DB.; ''Protein scaffolds in MAP kinase signalling.''; PubMed Europe PMC Scholia
  22. Hayes NV, Blackburn E, Smart LV, Boyle MM, Russell GA, Frost TM, Morgan BJ, Baines AJ, Gullick WJ.; ''Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer.''; PubMed Europe PMC Scholia
  23. Ni CY, Murphy MP, Golde TE, Carpenter G.; ''gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase.''; PubMed Europe PMC Scholia
  24. Pan D.; ''The hippo signaling pathway in development and cancer.''; PubMed Europe PMC Scholia
  25. Paoletti P, Bellone C, Zhou Q.; ''NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.''; PubMed Europe PMC Scholia
  26. Zeng F, Xu J, Harris RC.; ''Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells.''; PubMed Europe PMC Scholia
  27. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE.; ''The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.''; PubMed Europe PMC Scholia
  28. Lee KK, Ohyama T, Yajima N, Tsubuki S, Yonehara S.; ''MST, a physiological caspase substrate, highly sensitizes apoptosis both upstream and downstream of caspase activation.''; PubMed Europe PMC Scholia
  29. Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D.; ''ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.''; PubMed Europe PMC Scholia
  30. Gilmore-Hebert M, Ramabhadran R, Stern DF.; ''Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.''; PubMed Europe PMC Scholia
  31. Haskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfrán-Duque A, Suárez Y, Stern DF.; ''Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake.''; PubMed Europe PMC Scholia
  32. Geng F, Zhang J, Wu JL, Zou WJ, Liang ZP, Bi LL, Liu JH, Kong Y, Huang CQ, Li XW, Yang JM, Gao TM.; ''Neuregulin 1-ErbB4 signaling in the bed nucleus of the stria terminalis regulates anxiety-like behavior.''; PubMed Europe PMC Scholia
  33. Cohen S, Greenberg ME.; ''Communication between the synapse and the nucleus in neuronal development, plasticity, and disease.''; PubMed Europe PMC Scholia
  34. Kelly PA, Binart N, Freemark M, Lucas B, Goffin V, Bouchard B.; ''Prolactin receptor signal transduction pathways and actions determined in prolactin receptor knockout mice.''; PubMed Europe PMC Scholia
  35. Li Z, Mei Y, Liu X, Zhou M.; ''Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.''; PubMed Europe PMC Scholia
  36. Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K, Atfi A, Earp HS.; ''The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.''; PubMed Europe PMC Scholia
  37. Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA, McCall W, Sgagias MK, Cowan KH, Earp HS.; ''Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.''; PubMed Europe PMC Scholia
  38. Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE.; ''Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.''; PubMed Europe PMC Scholia
  39. Hou XJ, Ni KM, Yang JM, Li XM.; ''Neuregulin 1/ErbB4 enhances synchronized oscillations of prefrontal cortex neurons via inhibitory synapses.''; PubMed Europe PMC Scholia
  40. Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L, Gulino A, Alimandi M.; ''Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level.''; PubMed Europe PMC Scholia
  41. Arasada RR, Carpenter G.; ''Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment.''; PubMed Europe PMC Scholia
  42. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M.; ''Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.''; PubMed Europe PMC Scholia
  43. Del Pino I, García-Frigola C, Dehorter N, Brotons-Mas JR, Alvarez-Salvado E, Martínez de Lagrán M, Ciceri G, Gabaldón MV, Moratal D, Dierssen M, Canals S, Marín O, Rico B.; ''Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes.''; PubMed Europe PMC Scholia
  44. Riese DJ, Komurasaki T, Plowman GD, Stern DF.; ''Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.''; PubMed Europe PMC Scholia
  45. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G.; ''Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain.''; PubMed Europe PMC Scholia
  46. Omerovic J, Santangelo L, Puggioni EM, Marrocco J, Dall'Armi C, Palumbo C, Belleudi F, Di Marcotullio L, Frati L, Torrisi MR, Cesareni G, Gulino A, Alimandi M.; ''The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation.''; PubMed Europe PMC Scholia
  47. Cargnello M, Roux PP.; ''Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.''; PubMed Europe PMC Scholia
  48. Sun Y, Ikrar T, Davis MF, Gong N, Zheng X, Luo ZD, Lai C, Mei L, Holmes TC, Gandhi SP, Xu X.; ''Neuregulin-1/ErbB4 Signaling Regulates Visual Cortical Plasticity.''; PubMed Europe PMC Scholia
  49. Oh H, Irvine KD.; ''Yorkie: the final destination of Hippo signaling.''; PubMed Europe PMC Scholia
  50. Cantwell-Dorris ER, O'Leary JJ, Sheils OM.; ''BRAFV600E: implications for carcinogenesis and molecular therapy.''; PubMed Europe PMC Scholia
  51. Xiao L, Chen Y, Ji M, Dong J.; ''KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.''; PubMed Europe PMC Scholia
  52. Remue E, Meerschaert K, Oka T, Boucherie C, Vandekerckhove J, Sudol M, Gettemans J.; ''TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner.''; PubMed Europe PMC Scholia
  53. Cohen BD, Green JM, Foy L, Fell HP.; ''HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers.''; PubMed Europe PMC Scholia
  54. Andersson ER, Lendahl U.; ''Therapeutic modulation of Notch signalling--are we there yet?''; PubMed Europe PMC Scholia
  55. Sweeney C, Lai C, Riese DJ, Diamonti AJ, Cantley LC, Carraway KL.; ''Ligand discrimination in signaling through an ErbB4 receptor homodimer.''; PubMed Europe PMC Scholia
  56. Woo RS, Lee JH, Kim HS, Baek CH, Song DY, Suh YH, Baik TK.; ''Neuregulin-1 protects against neurotoxicities induced by Swedish amyloid precursor protein via the ErbB4 receptor.''; PubMed Europe PMC Scholia
  57. Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ.; ''Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4.''; PubMed Europe PMC Scholia
  58. Paatero I, Jokilammi A, Heikkinen PT, Iljin K, Kallioniemi OP, Jones FE, Jaakkola PM, Elenius K.; ''Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.''; PubMed Europe PMC Scholia
  59. Fukumoto T, Kubota Y, Kitanaka A, Yamaoka G, Ohara-Waki F, Imataki O, Ohnishi H, Ishida T, Tanaka T.; ''Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.''; PubMed Europe PMC Scholia
  60. Kyriakis JM, Avruch J.; ''Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update.''; PubMed Europe PMC Scholia
  61. Guan YF, Wu CY, Fang YY, Zeng YN, Luo ZY, Li SJ, Li XW, Zhu XH, Mei L, Gao TM.; ''Neuregulin 1 protects against ischemic brain injury via ErbB4 receptors by increasing GABAergic transmission.''; PubMed Europe PMC Scholia
  62. Schulze WX, Deng L, Mann M.; ''Phosphotyrosine interactome of the ErbB-receptor kinase family.''; PubMed Europe PMC Scholia
  63. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA.; ''Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice.''; PubMed Europe PMC Scholia
  64. Zhao B, Li L, Lei Q, Guan KL.; ''The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version.''; PubMed Europe PMC Scholia
  65. Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K.; ''A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.''; PubMed Europe PMC Scholia
  66. Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE.; ''The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.''; PubMed Europe PMC Scholia
  67. Mitchell RM, Janssen MJ, Karavanova I, Vullhorst D, Furth K, Makusky A, Markey SP, Buonanno A.; ''ErbB4 reduces synaptic GABAA currents independent of its receptor tyrosine kinase activity.''; PubMed Europe PMC Scholia
  68. Sudol M, Harvey KF.; ''Modularity in the Hippo signaling pathway.''; PubMed Europe PMC Scholia
  69. Ishibashi K, Fukumoto Y, Hasegawa H, Abe K, Kubota S, Aoyama K, Kubota S, Nakayama Y, Yamaguchi N.; ''Nuclear ErbB4 signaling through H3K9me3 is antagonized by EGFR-activated c-Src.''; PubMed Europe PMC Scholia
  70. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y.; ''Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.'';